Skip to main content

Table 1 Patient characteristics

From: HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma

Characteristics N % HPV Positive
N (%)
HPV Negative
N (%)
p-value
Age      0.361
 < 65 years old 44 56.4%    
 ≥ 65 years old 34 43.6% 35 (59.3) 9 (47.4)  
Gender    24 (40.7) 10 (52.6) 0.004
 Female 64 82.1    
 Male 14 17.9 53 (89.8) 11 (57.9)  
Degree of Cellular Differentiation    6 (10.2) 8 (42.1) 0.351
 G I 6 7.7    
 G II 58 74.4 6 (10.2) 0 (0)  
 G III 11 14.1 42 (71.2) 16 (84.2)  
 G IV 3 3.8 8 (13.6) 3 (15.8)  
Clinical Stage (UICC)    3 (5.1) 0 (0) 0.031
 I 5 6.4    
 II 47 60.3 5 (8.5) 0 (0)  
 IIIA 16 20.5 39 (66.1) 8 (42.1)  
 IIIB 10 12.8 8 (13.6) 8 (42.1)  
N Stage    7 (11.9) 3 (15.8) 0.354
 Negative 60 76.9    
 Positive 18 23.1 47 (79.7) 13 (68.4)  
T Stage    12 (20.3) 6 (31.6) 0,012
 T1 (≤ 2 cm) 6 7.7    
 T2 (> 2 and ≤5 cm) 30 38.5 6 (10.2) 0 (0)  
 T3 (>  5 cm) 30 38.5 27 (45.8) 3 (15.8)  
 T4 (tumour invading adjacent organ) 12 15.4 20 (33.9) 10 (52.6)  
HPV    6 (10.2) 6 (31.6) NA
 16 49 62.8    
 18 10 12.8 49 (62.8) 0 (0)  
 Negative 19 24.4 10 (12.8) 0 (0)  
HIV    19 (24.4) 0 (0) 1.000
Positive 19 24.4    
Negative 59 75.6 14 (23.7) 5 (26.3)  
P16    45 (76.3) 14 (73.7) < 0.001
 Positive 57 73.1    
 Negative 19 24.4 57 (96.6) 0 (0)  
Borderline 2 2.6 0 (0) 19 (100.0)  
Clinical response at 6 months    2 (3.4) 0 (0) < 0.001
 Yes 47 60.3    
 No 31 39.7 47 (79.7) 0 (0)  
TP53    12 (20.3) 19 (100.0) < 0.001
 Mutated 21 26.9    
 Wild type 57 73.1 2 (3.4) 19 (100.0)  
Total 78 100.0 57 (96.6) 0 (0)  
  1. NA = Not available
  2. Statistically significant p-values are shown in bold